This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lodise, T. P.
Right arrow Articles by Drusano, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lodise, T. P., Jr.
Right arrow Articles by Drusano, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2007, p. 2378-2387, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.01181-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects{triangledown}

Thomas P. Lodise Jr.,1,2 Rienk Pypstra,3 James B. Kahn,4 Bindu P. Murthy,5 Hui C. Kimko,5 Karen Bush,5 Gary J. Noel,5 and George L. Drusano1*

Ordway Research Institute, Albany, New York,1 Albany College of Pharmacy, Albany, New York,2 Basilea Pharmaceutica, Basel, Switzerland,3 Janssen-Ortho, Raritan, New Jersey,4 Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey5

Received 21 September 2006/ Returned for modification 31 October 2006/ Accepted 17 March 2007

Ceftobiprole is a broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA) that is undergoing phase III trials for the treatment of complicated skin and skin structure infections and nosocomial pneumonia. The objectives were to describe the pharmacodynamic profiles of ceftobiprole given at 500 mg intravenously (i.v.) every 8 h (q8h) (2-h infusion) and 500 mg i.v. every 12 h (q12h) (1-h infusion) to determine the overall probability of target attainment (PTA) by weighting for the expected distributions of renal function in the populations of interests, to determine the PTA against representative pathogens encountered in clinical trials, and to determine the optimal renal dose adjustment for ceftobiprole at 500 mg i.v. q8h (2-h infusion). Data for a total of 150 subjects in phase I/II trials were analyzed by using the population pharmacokinetic modeling program BigNPOD (nonparametric optimal design). Monte Carlo simulation was performed with the ADAPT II program to estimate the PTA at which the free drug concentrations exceed the MIC for 30 to 60% of the dosing interval (30 to 60% fT > MIC). For ceftobiprole at 500 mg i.v. q12h, the probabilities of achieving 30% and 50% fT > MIC exceeded 90% for MICs ≤2 mg/liter and ≤1 mg/liter, respectively, For ceftobiprole at 500 mg i.v. q8h, the probabilities of achieving 40 and 60% fT > MIC exceeded 90% for MICs ≤4 mg/liter and ≤2 mg/liter, respectively. For ceftobiprole at both 500 mg i.v. q12h and 500 mg i.v. q8h, the probability of achieving a nearly bactericidal effect (50% fT > MIC) exceeded 90% for methicillin-susceptible S. aureus and MRSA. For gram-negative pathogens, the PTA for achieving a nearly maximal bactericidal effect (60% fT > MIC) for ceftobiprole at 500 mg i.v. q8h exceeded 90% for non-AmpC-producing gram-negative organisms. Ceftobiprole at 500 mg i.v. q12h, for patients who had a creatinine clearance rate of ≤50 ml/min, was identified as the most appropriate treatment regimen for patients who require renal dose adjustment for mild to moderate renal impairment.

* Corresponding author. Mailing address: Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208. Phone: (518) 641-6434. Fax: (518) 641-6304. E-mail: gdrusano{at}ordwayresearch.org

{triangledown} Published ahead of print on 26 March 2007.

Antimicrobial Agents and Chemotherapy, July 2007, p. 2378-2387, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.01181-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Borbone, S., Campanile, F., Bongiorno, D., Stefani, S. (2010). In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 65: 591-594 [Full Text]  
  • Vidaillac, C., Leonard, S. N., Rybak, M. J. (2009). In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model. Antimicrob. Agents Chemother. 53: 4712-4717 [Abstract] [Full Text]  
  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  
  • Rodvold, K. A., Nicolau, D. P., Lodise, T. P., Khashab, M., Noel, G. J., Kahn, J. B., Gotfried, M., Murray, S. A., Nicholson, S., Laohavaleeson, S., Tessier, P. R., Drusano, G. L. (2009). Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrob. Agents Chemother. 53: 3294-3301 [Abstract] [Full Text]  
  • Kimko, H., Xu, X., Nandy, P., Samtani, M. N., Strauss, R. S., Bagchi, P., Noel, G. J. (2009). Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 3371-3374 [Abstract] [Full Text]  
  • Amsler, K. M., Davies, T. A., Shang, W., Jacobs, M. R., Bush, K. (2008). In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 52: 3418-3423 [Abstract] [Full Text]  
  • Banerjee, R., Gretes, M., Basuino, L., Strynadka, N., Chambers, H. F. (2008). In Vitro Selection and Characterization of Ceftobiprole-Resistant Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2089-2096 [Abstract] [Full Text]  
  • Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
  • Noel, G. J., Strauss, R. S., Amsler, K., Heep, M., Pypstra, R., Solomkin, J. S. (2008). Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 37-44 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»